News

Recipharm, the Swedish CDMO, which happens to be Moderna’s COVID-19 vaccine production partner, has undergone not one but two acquisitions in the week ending February 19th. This expansion is a part of a strategy that Recipharm has been eyeing...

Xanadu Bio, in association with Yale University, has come up with a nanoparticle delivery platform that will help to position itself to give its expertise in the COVID-19 booster vaccines that may prove to be more efficient in stopping...

Recipharm, a global contract development and manufacturing organisation (CDMO), is continuing to build its service offerings in new biologic modalities through the acquisition of Vibalogics, a virotherapy CDMO and a portfolio company of Ampersand Capital Partners. Vibalogics holds a...

A contract extension has been put in place between Moderna, Inc. and Spain’s Rovi, which shall cover the production of formers vaccine doses, including any future mRNA-based drugs as well as immunizations. Notably, the contract between the two organisations...

In order to increase access to treatments that are recommended to fight COVID-19, the WHO has added a monoclonal antibody treatment called Tocilizumab to its list of prequalified options to treat the virus. Currently, the WHO has given a nod...

Collegium Pharmaceutical, Inc. and BioDelivery Sciences International, Inc. announced a definitive agreement pursuant to which Collegium will acquire BDSI for $5.60 per share in cash. BDSI has a portfolio of pain and neurology products that address serious and debilitating conditions....

ImmunityBio, Inc., a clinical-stage immunotherapy company announced the successful completion of its acquisition of the leasehold interest in an ISO Class 5 pharmaceutical manufacturing space in western New York from global pharmaceutical company Athenex, Inc. (NASDAQ: ATNX). The new state-of-the-art...